Tobacco smoking and alcohol consumption as risk factors for thymoma - A European case-control study.


Journal

Cancer epidemiology
ISSN: 1877-783X
Titre abrégé: Cancer Epidemiol
Pays: Netherlands
ID NLM: 101508793

Informations de publication

Date de publication:
08 2019
Historique:
received: 20 02 2019
revised: 26 05 2019
accepted: 19 06 2019
pubmed: 30 6 2019
medline: 26 3 2020
entrez: 30 6 2019
Statut: ppublish

Résumé

Hardly anything is known about the aetiology of thymoma. This paper presents data regarding tobacco smoking and alcohol consumption in relation to thymoma from the first case-control study performed on this rare tumour. A European multi-centre case-control study including incident cases aged 35-69 years with thymoma between 1995 and 1997, was conducted in seven countries. A set of controls, used in seven parallel case-control studies by the same research group was used, including population-based controls from five countries and hospital controls with colon cancer from two countries. Altogether 103 cases, accepted by a reference pathologist, 712 colon cancer controls, and 2071 population controls were interviewed. Tobacco smoking was moderately related with thymoma (OR 1.4, 95% CI 0.9-2.2), and a tendency to dose-response was shown (p = 0.04), with an increased risk for heavy smokers defined as ≥41 pack-years (OR 2.1, 95% CI 1.1-3.9). A high consumption of spirits defined as ≥25 g of alcohol per day was associated with an increased risk of thymoma (OR 2.4, 95% CI 1.1-5.4), whereas no association was found with beer or wine. Tobacco smoking and a high intake of spirits were indicated as risk factors for thymoma.

Identifiants

pubmed: 31254794
pii: S1877-7821(19)30058-X
doi: 10.1016/j.canep.2019.06.008
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

133-138

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Auteurs

Mikael Eriksson (M)

Department of Oncology, Lund University, and Skane University Hospital, Lund, Sweden. Electronic address: mikael.eriksson@med.lu.se.

Linda Kaerlev (L)

Research Unit of Clinical Epidemiology, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark; Center for Clinical Epidemiology, Odense University Hospital, Odense, Denmark.

Preben Johansen (P)

Institute of Pathology, Aalborg Hospital, Aalborg, Denmark.

Noemia Afonso (N)

Medical Oncology Department, Instituto Português de Oncologia (IPO-Porto), Porto, Portugal.

Wolfgang Ahrens (W)

Department of Epidemiological Methods and Etiologic Research, Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany.

Altamiro Costa-Pereira (A)

Department of Health Information and Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.

Pascal Guénel (P)

Centre de recherche en Épidémiologie et Santé des Populations (CESP), Inserm U1018, France; Cancer and Environment Team, Université Paris-Sud, Villejuif, France.

Karl-Heinz Jöckel (KH)

Institute for Medical Informatics, Biometry and Epidemiology, University Clinic Essen, Germany.

Agustin Llopis Gonzalez (AL)

Unit of Public Health and Environmental Care, Department of Preventive Medicine, University of Valencia, Valencia, Spain; CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.

Franco Merletti (F)

Unit of Cancer Epidemiology, Centre for Oncologic Prevention, University of Turin, Italy.

Maria Morales Suárez-Varela (MM)

Unit of Public Health and Environmental Care, Department of Preventive Medicine, University of Valencia, Valencia, Spain; CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.

Brigitte Trétarre (B)

Registre des Tumeurs de l´Hérault, Montpellier, France.

Gun Wingren (G)

Division of Occupational and Environmental Medicine, Department of Clinical and Experimental Medicine, Linköping University, Sweden.

Lorenzo Richiardi (L)

Department of Oncology, University of Padua, Italy.

Svend Sabroe (S)

Department of Public Health, University of Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH